Compare RDY & ALLY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RDY | ALLY |
|---|---|---|
| Founded | 1984 | 1919 |
| Country | India | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.6B | 12.9B |
| IPO Year | N/A | 2014 |
| Metric | RDY | ALLY |
|---|---|---|
| Price | $14.13 | $42.36 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 17 |
| Target Price | $16.90 | ★ $46.33 |
| AVG Volume (30 Days) | 923.2K | ★ 2.8M |
| Earning Date | 01-22-2026 | 01-21-2026 |
| Dividend Yield | 0.50% | ★ 2.83% |
| EPS Growth | 9.95 | ★ 11.52 |
| EPS | 0.79 | ★ 1.67 |
| Revenue | $3,851,623,984.00 | ★ $7,171,000,000.00 |
| Revenue This Year | $6.16 | $20.26 |
| Revenue Next Year | $2.57 | $14.12 |
| P/E Ratio | ★ $17.94 | $25.43 |
| Revenue Growth | ★ 14.10 | 6.02 |
| 52 Week Low | $12.26 | $29.52 |
| 52 Week High | $16.17 | $44.83 |
| Indicator | RDY | ALLY |
|---|---|---|
| Relative Strength Index (RSI) | 55.76 | 64.24 |
| Support Level | $13.64 | $37.51 |
| Resistance Level | $14.20 | $41.77 |
| Average True Range (ATR) | 0.17 | 1.05 |
| MACD | 0.05 | 0.39 |
| Stochastic Oscillator | 88.39 | 93.66 |
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (about 20% of its generics sales), Russia (10%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.
Formerly the captive financial arm of General Motors, Ally Financial became an independent publicly traded firm in 2014 and is one of the largest consumer auto lenders in the country. While the firm has expanded its product offerings over time, it remains primarily focused on auto lending, with more than 70% of its loan book in consumer auto loans and dealer financing. Ally also offers auto insurance, commercial loans, credit cards, and holds a portfolio of mortgage debt, giving the bank a diversified business model, which includes brokerage services.